Endothelin and Endothelin Antagonists in Chronic Kidney Disease

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2014 May 9

PMID 24805108

Citations 121

Authors

Donald E Kohan

Matthias Barton

Affiliations

Soon will be listed here.

Abstract

The incidence and prevalence of chronic kidney disease (CKD), with diabetes and hypertension accounting for the majority of cases, is on the rise, with up to 160 million individuals worldwide predicted to be affected by 2020. Given that current treatment options, primarily targeted at the renin-angiotensin system, only modestly slow down progression to end-stage renal disease, the urgent need for additional effective therapeutics is evident. Endothelin-1 (ET-1), largely through activation of endothelin A receptors, has been strongly implicated in renal cell injury, proteinuria, inflammation, and fibrosis leading to CKD. Endothelin receptor antagonists (ERAs) have been demonstrated to ameliorate or even reverse renal injury and/or fibrosis in experimental models of CKD, whereas clinical trials indicate a substantial antiproteinuric effect of ERAs in diabetic and nondiabetic CKD patients even on top of maximal renin-angiotensin system blockade. This review summarizes the role of ET in CKD pathogenesis and discusses the potential therapeutic benefit of targeting the ET system in CKD, with attention to the risks and benefits of such an approach.

Citing Articles

The role of endothelin receptor antagonists in kidney disease.

Ma X, Liang Y, Chen W, Zheng L, Lin H, Zhou T Ren Fail. 2025; 47(1):2465810.

PMID: 40015728 PMC: 11869344. DOI: 10.1080/0886022X.2025.2465810.

The association between anion gap and prognosis in patients myocardial infarction with congestive heart failure: a retrospective analysis of the MIMIC-IV database.

Li M, Li C, Wang J, Yuan Q Int J Emerg Med. 2025; 18(1):33.

PMID: 39994567 PMC: 11849230. DOI: 10.1186/s12245-025-00828-0.

Advances and challenges in kidney fibrosis therapeutics.

Abbad L, Esteve E, Chatziantoniou C Nat Rev Nephrol. 2025; .

PMID: 39934355 DOI: 10.1038/s41581-025-00934-5.

Upcoming drug targets for kidney protective effects in chronic kidney disease.

Nardone M, Yau K, Kugathasan L, Odutayo A, Mohsen M, Ouimet J Nephrol Dial Transplant. 2025; 40(Supplement_1):i47-i58.

PMID: 39907540 PMC: 11852282. DOI: 10.1093/ndt/gfae216.

Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.

Moedt E, Wasehuus V, Heerspink H Nephrol Dial Transplant. 2025; 40(Supplement_1):i37-i46.

PMID: 39907539 PMC: 11795649. DOI: 10.1093/ndt/gfae214.

References

Barton M . Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol. 2008; 4(9):490-501. DOI: 10.1038/ncpneph0891. View

Sasser J, Sullivan J, Hobbs J, Yamamoto T, Pollock D, Carmines P . Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol. 2006; 18(1):143-54. PMC: 2579758. DOI: 10.1681/ASN.2006030208. View

Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V . Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest. 1997; 99(6):1380-9. PMC: 507954. DOI: 10.1172/JCI119297. View

Hartleben B, Godel M, Meyer-Schwesinger C, Liu S, Ulrich T, Kobler S . Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010; 120(4):1084-96. PMC: 2846040. DOI: 10.1172/JCI39492. View

Placier S, Boffa J, Dussaule J, Chatziantoniou C . Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant. 2005; 21(4):881-8. DOI: 10.1093/ndt/gfk004. View

Barton M, Tharaux P . Endothelin and the podocyte. Clin Kidney J. 2015; 5(1):17-27. PMC: 4400467. DOI: 10.1093/ckj/sfs001. View

Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth P . Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science. 1998; 280(5366):1069-72. DOI: 10.1126/science.280.5366.1069. View

Mahajan A, Simoni J, Sheather S, Broglio K, Rajab M, Wesson D . Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010; 78(3):303-9. DOI: 10.1038/ki.2010.129. View

Boffa J, Tharaux P, Dussaule J, Chatziantoniou C . Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension. 2001; 37(2 Pt 2):490-6. DOI: 10.1161/01.hyp.37.2.490. View

10.

Dhaun N, Ferro C, Davenport A, Haynes W, Goddard J, Webb D . Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant. 2007; 22(11):3228-34. DOI: 10.1093/ndt/gfm364. View

11.

Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C . Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008; 294(5):F1185-94. DOI: 10.1152/ajprenal.00442.2007. View

12.

Gross M, Ritz E, Schoof A, Helmke B, Parkman A, Tulp O . Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest. 2003; 83(9):1267-77. DOI: 10.1097/01.lab.0000085188.23709.29. View

13.

Kelsen S, Hall J, Chade A . Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol. 2011; 301(1):F218-25. PMC: 3129888. DOI: 10.1152/ajprenal.00089.2011. View

14.

Kassab S, MILLER M, Novak J, Reckelhoff J, Clower B, Granger J . Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension. 1998; 31(1 Pt 2):397-402. DOI: 10.1161/01.hyp.31.1.397. View

15.

Fligny C, Barton M, Tharaux P . Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol. 2011; 172:120-138. DOI: 10.1159/000328692. View

16.

Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C . In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005; 166(5):1309-20. PMC: 1606387. DOI: 10.1016/S0002-9440(10)62350-4. View

17.

Barton M, Vos I, Shaw S, Boer P, Duscio L, Grone H . Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis. J Am Soc Nephrol. 2000; 11(5):835-845. DOI: 10.1681/ASN.V115835. View

18.

Kohan D . Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997; 29(1):2-26. DOI: 10.1016/s0272-6386(97)90004-4. View

19.

Speed J, Pollock D . Endothelin, kidney disease, and hypertension. Hypertension. 2013; 61(6):1142-5. PMC: 3804114. DOI: 10.1161/HYPERTENSIONAHA.113.00595. View

20.

Saleh M, Boesen E, Pollock J, Savin V, Pollock D . Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010; 56(5):942-9. PMC: 2959121. DOI: 10.1161/HYPERTENSIONAHA.110.156570. View